Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 64.24% is in line with its 5-year average of 61.76%, near the high end of its 5-year range (57.23%–65.00%).
0.24% below its 12-month average of 64.39%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 64.84%.
GROSS MARGIN
64.24%
GROSS MARGIN AVG TTM
64.39%
GROSS MARGIN AVG 3Y
62.73%
GROSS MARGIN AVG 5Y
61.76%
GROSS MARGIN AVG 10Y
57.42%
GROSS MARGIN AVG 15Y
49.70%
GROSS MARGIN AVG 20Y
44.01%
CURRENT VS TTM AVG
-0.24%
CURRENT VS 3Y AVG
+2.40%
CURRENT VS 5Y AVG
+4.02%
CURRENT VS 10Y AVG
+11.87%
CURRENT VS 15Y AVG
+29.26%
CURRENT VS 20Y AVG
+45.96%
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+55.24%
vs the sector median at left
Niagen Bioscience Inc
Market Cap
$213.53M
Gross Margin
64.24%
TTM Avg
64.39%
3Y Avg
62.73%
5Y Avg
61.76%
Market Cap
$213.71M
Gross Margin
-31952.78%
TTM Avg
-15926.39%
3Y Avg
-7913.19%
5Y Avg
-5242.13%
Market Cap
$215.21M
Gross Margin
85.91%
TTM Avg
92.95%
3Y Avg
46.48%
5Y Avg
30.98%
Market Cap
$212.43M
Gross Margin
87.24%
TTM Avg
79.57%
3Y Avg
65.64%
5Y Avg
63.99%
Market Cap
$210.80M
Gross Margin
83.89%
TTM Avg
91.94%
3Y Avg
70.97%
5Y Avg
47.31%
Market Cap
$207.18M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niagen Bioscience Inc (NAGE) | $213.53M | 64.24% | 64.39% | 62.73% | 61.76% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $213.71M | -31952.78% | -15926.39% | -7913.19% | -5242.13% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $215.21M | 85.91% | 92.95% | 46.48% | 30.98% |
| Compugen Ltd. (CGEN)vs › | $211.33M | 86.89% | 79.42% | 84.96% | 87.58% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $212.43M | 87.24% | 79.57% | 65.64% | 63.99% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.80M | 83.89% | 91.94% | 70.97% | 47.31% |
| Pro-Dex, Inc. (PDEX)vs › | $207.81M | 31.38% | 30.34% | 28.84% | 29.64% |
| Sionna Therapeutics, Inc. (SION)vs › | $207.18M | 0.00% | 0.00% | 0.00% | 0.00% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.50M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $221.45M | 94.68% | 99.69% | 74.84% | 66.56% |
Gross Margin
64.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 64.84% |
| 2026-03-31 | 63.47% |
| 2025-12-31 | 64.14% |
| 2025-09-30 | 64.52% |
| 2025-06-30 | 65.00% |
| 2025-03-31 | 63.42% |
| 2024-12-31 | 62.48% |
| 2024-09-30 | 63.49% |
| 2024-06-30 | 60.22% |
| 2024-03-31 | 60.74% |
| 2023-12-31 | 61.04% |
| 2023-09-30 | 61.40% |
| 2023-06-30 | 60.80% |
| 2023-03-31 | 59.93% |
| 2022-12-31 | 57.23% |
| 2022-09-30 | 59.82% |
| 2022-06-30 | 60.02% |
| 2022-03-31 | 61.02% |
| 2021-12-31 | 61.20% |
| 2021-09-30 | 61.12% |
| 2021-06-30 | 61.08% |
| 2021-03-31 | 62.89% |
| 2020-12-31 | 61.00% |
| 2020-09-30 | 59.62% |
| 2020-06-30 | 59.45% |
| 2020-03-31 | 57.94% |
| 2019-12-31 | 57.03% |
| 2019-09-30 | 55.99% |
| 2019-06-30 | 56.34% |
| 2019-03-31 | 52.76% |
| 2018-12-31 | 51.96% |
| 2018-09-30 | 53.71% |
| 2018-06-30 | 49.29% |
| 2018-03-31 | 47.77% |
| 2017-12-31 | 50.92% |
| 2017-09-30 | 47.91% |
| 2017-06-30 | 50.00% |
| 2017-03-31 | 48.04% |
| 2016-12-31 | 40.76% |
| 2016-09-30 | 47.32% |
| 2016-06-30 | 46.75% |
| 2016-03-31 | 47.07% |
| 2015-12-31 | 36.68% |
| 2015-09-30 | 39.47% |
| 2015-06-30 | 40.49% |
| 2015-03-31 | 36.64% |
| 2014-12-31 | 33.44% |
| 2014-09-30 | 36.79% |
| 2014-06-30 | 36.27% |
| 2014-03-31 | 32.04% |
| 2013-12-31 | 31.21% |
| 2013-09-30 | 27.60% |
| 2013-06-30 | 35.49% |
| 2013-03-31 | 28.82% |
| 2012-12-31 | 24.43% |
| 2012-09-30 | 34.53% |
| 2012-06-30 | 28.63% |
| 2012-03-31 | -33.85% |
| 2011-12-31 | 22.35% |
| 2011-09-30 | 25.52% |
| 2011-06-30 | 29.98% |
| 2011-03-31 | 40.18% |
| 2010-12-31 | 41.74% |
| 2010-09-30 | 32.18% |
| 2010-06-30 | 38.14% |
| 2010-03-31 | 42.22% |
| 2009-12-31 | 39.59% |
| 2009-09-30 | 33.50% |
| 2009-06-30 | 35.57% |
| 2009-03-31 | 32.34% |
| 2008-12-31 | 23.66% |
| 2008-09-30 | 17.51% |
| 2008-06-30 | 30.53% |
| 2008-02-29 | 0.00% |
| 2007-11-30 | 0.00% |
| 2007-08-31 | 0.00% |
| 2007-05-31 | 0.00% |
| 2007-02-28 | 0.00% |
